TY - JOUR
T1 - Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies
AU - Pesarrodona, Mireia
AU - Jauset, Toni
AU - Díaz-Riascos, Zamira V.
AU - Sánchez-Chardi, Alejandro
AU - Beaulieu, Marie Eve
AU - Seras-Franzoso, Joaquin
AU - Sánchez-García, Laura
AU - Baltà-Foix, Ricardo
AU - Mancilla, Sandra
AU - Fernández, Yolanda
AU - Rinas, Ursula
AU - Schwartz, Simó
AU - Soucek, Laura
AU - Villaverde, Antonio
AU - Abasolo, Ibane
AU - Vázquez, Esther
PY - 2019/9/1
Y1 - 2019/9/1
N2 - © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
AB - © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
KW - biofabrication
KW - cancer therapy
KW - functional amyloids
KW - inclusion bodies
KW - protein drug release
U2 - 10.1002/advs.201900849
DO - 10.1002/advs.201900849
M3 - Article
C2 - 31559131
VL - 6
JO - Advanced Science
JF - Advanced Science
SN - 2198-3844
M1 - 1900849
ER -